The severity of AD as assessed by the lesion length was 8.53 ± 1.76 mm (mean ± standard errors, n = 10) for the vehicle group and 3.84 ± 1.55 mm (n = 13) for the rapamycin group (p < 0.05, Table 3, Figure 6), indicating that rapamycin can ameliorate the progression of AD after the start of the BAPN + AngII challenge. The gene discussed is AGT; the disease is Alzheimer disease.